We are live on ! Find out more
SUPN icon

Supernus Pharmaceuticals
SUPN

119 hedge funds and large institutions have $491M invested in Supernus Pharmaceuticals in 2015 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 45 increasing their positions, 31 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

92% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 13

85% more call options, than puts

Call options by funds: $4.93M | Put options by funds: $2.67M

75% more funds holding in top 10

Funds holding in top 10: 4 → 7 (+3)

59% more capital invested

Capital invested by funds: $309M → $491M (+$182M)

45% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 31

11% more funds holding

Funds holding: 107 → 119 (+12)

Holders
119
Holders Change
+12
Holders Change %
+11.21%
% of All Funds
3.17%
Holding in Top 10
7
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+75%
% of All Funds
0.19%
New
25
Increased
45
Reduced
31
Closed
13
Calls
$4.93M
Puts
$2.67M
Net Calls
+$2.26M
Net Calls Change
+$1.25M

Top Buyers

1
CCM
Consonance Capital Management
New York
+$33.7M
2
KCM
Kennedy Capital Management
Missouri
+$5.1M
3
ACM
Ashford Capital Management
Delaware
+$2.47M
4
CWG
C WorldWide Group
Denmark
+$2.36M
5
NC
Northpointe Capital
Michigan
+$2.15M

Top Sellers

1
AAP
Ardsley Advisory Partners
Connecticut
-$8.59M
2
A
Abingworth
United Kingdom
-$5.44M
3
MRM
Michael R. Murphy
-$4.26M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$3.41M
5
TC
TFS Capital
Pennsylvania
-$2.55M
Name Holding Trade Value Shares
Change 		Change in
Stake
NMC
1
NEA Management Company
Maryland
$129M – – –
CCM
2
Consonance Capital Management
New York
$43.1M +$33.7M +3,566,923 New
MRM
3
Michael R. Murphy
$32M -$4.26M -451,018 -15%
A
4
Abingworth
United Kingdom
$27.8M -$5.44M -575,866 -20%
Ameriprise
5
Ameriprise
Minnesota
$17.3M -$366K -38,712 -3%
BFA
6
BlackRock Fund Advisors
California
$16.4M +$211K +22,301 +2%
NC
7
Northpointe Capital
Michigan
$14.6M +$2.15M +227,196 +23%
T. Rowe Price Associates
8
T. Rowe Price Associates
Maryland
$12.8M -$3.41M -360,382 -25%
AAP
9
Ardsley Advisory Partners
Connecticut
$11.9M -$8.59M -908,700 -48%
Vanguard Group
10
Vanguard Group
Pennsylvania
$10.7M +$606K +64,120 +8%
MOACM
11
Mutual of America Capital Management
New York
$8.74M -$366K -38,724 -5%
BC
12
Bruce & Co
Illinois
$8.33M – – –
ACM
13
Ashford Capital Management
Delaware
$8.22M +$2.47M +261,587 +63%
KCM
14
Kennedy Capital Management
Missouri
$8.1M +$5.1M +539,985 +415%
KIA
15
Kopp Investment Advisors
Minnesota
$7.42M +$78.9K +8,345 +1%
O
16
OrbiMed
New York
$7.01M – – –
AIS
17
AlphaOne Investment Services
Pennsylvania
$6.76M +$823K +87,050 +18%
OM
18
Opaleye Management
Massachusetts
$6.47M +$1.75M +185,000 +53%
IHM
19
Iguana Healthcare Management
New York
$6.04M – – –
WA
20
Whitebox Advisors
Minnesota
$5.5M +$328K +34,707 +8%
RPAM
21
Rhenman & Partners Asset Management
Sweden
$5.45M +$1.89M +200,000 +80%
Millennium Management
22
Millennium Management
New York
$5.13M -$1.29M -136,120 -24%
CWG
23
C WorldWide Group
Denmark
$4.59M +$2.36M +250,000 +192%
BIT
24
BlackRock Institutional Trust
California
$4.54M +$929K +98,299 +35%
State Street
25
State Street
Massachusetts
$4.38M +$573K +60,662 +20%
1
2 3 4 5

SUPN Hedge Fund Activity: Q1 2015 in Review

119 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q1 2015, worth a combined $491M — up 59% from $309M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new SUPN positions and 13 closed out — a net gain of 12 holders — while 45 added to existing stakes and 31 trimmed.

The largest buyer was Consonance Capital Management, opening a new position worth an estimated $33.7M. The largest seller was Ardsley Advisory Partners, cutting an estimated $8.59M.

  • 119 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q1 2015, up from 107 in Q4 2014.
  • Funds reported $491M of Supernus Pharmaceuticals stock for Q1 2015, up 59% quarter-over-quarter.
  • 25 funds opened new Supernus Pharmaceuticals positions in Q1 2015 and 13 closed out, a net change of +12 holders.
  • The largest Supernus Pharmaceuticals buyer in Q1 2015 was Consonance Capital Management, an estimated $33.7M added.
  • The largest Supernus Pharmaceuticals seller in Q1 2015 was Ardsley Advisory Partners, an estimated $8.59M sold.

Based on aggregated 13F filings for Q1 2015.